In Reply We would like to thank Dr Bramati and colleagues for their comments regarding our randomized clinical trial.1 They highlighted the critical need to translate the science demonstrating the benefits of specialty palliative care for patients with hematologic cancers into oncology practice. We agree wholeheartedly and want to emphasize the need for further dissemination and implementation research to ensure uptake, adoption, and sustainability of palliative care integration for patients with hematologic cancers across care settings. Dissemination and implementation research will also provide us with an opportunity to study the potential barriers and facilitators for integrating palliative care for patients with hematologic cancers in diverse, real-world clinical settings.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
El-Jawahri A, LeBlanc TW, Temel JS. Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia—Moving From Evidence to Practice—Reply. JAMA Oncol. 2021;7(6):943–944. doi:10.1001/jamaoncol.2021.0709
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: